论文部分内容阅读
目的探讨ERp29在胃癌中的表达及其与临床病理特征、预后等之间的关系。方法通过免疫组化检测胃癌组织及癌旁组织中ERp29的表达情况,并分析ERp29与临床病理特征及预后的相关性。结果 ERp29在胃癌旁组织及癌组织中的阳性表达率分别为为80.48%(66/82)、45.12%(37/82),两者相比差异具有统计学意义(P<0.05)。ERp29的表达与患者年龄、性别、肿瘤部位、癌组织学类型及局部浸润深度等无明显相关性,但与肿瘤TNM分期及淋巴结转移呈负相关。ERp29表达阳性患者的3年生存率、平均生存期均高于阴性组患者。结论胃癌组织ERp29的表达下降,并且与肿瘤的临床病理特征及预后相关,提示ERp29是一个潜在抑癌基因。
Objective To investigate the expression of ERp29 in gastric cancer and its relationship with clinicopathological characteristics, prognosis and so on. Methods The expression of ERp29 in gastric cancer tissues and adjacent tissues was detected by immunohistochemistry. The correlation between ERp29 expression and the clinicopathological features and prognosis was analyzed. Results The positive expression rates of ERp29 in gastric cancer tissues and adjacent tissues were 80.48% (66/82) and 45.12% (37/82), respectively. There was significant difference between them (P <0.05). The expression of ERp29 had no significant correlation with age, sex, tumor location, histological type and depth of local invasion, but negatively correlated with TNM staging and lymph node metastasis. The 3-year survival rate and mean survival time of patients with positive expression of ERp29 were higher than those of patients with negative expression. Conclusions The expression of ERp29 in gastric cancer is decreased, and it is correlated with the clinicopathological features and prognosis of the tumor, suggesting that ERp29 is a potential tumor suppressor gene.